Relay Therapeutics (RLAY) Current Assets (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Current Assets data on file, last reported at $658.5 million in Q1 2026.

• On a quarterly basis, Current Assets fell 10.98% year-over-year to $658.5 million in Q1 2026; TTM through Mar 2026 was $658.5 million, a 10.98% decrease from a year earlier, with the FY2025 full-year figure at $578.3 million, down 28.54% from the prior year.
• Current Assets for Q1 2026 stood at $658.5 million, up from $578.3 million in the prior quarter.
• Over the last five years, Current Assets for RLAY reached as high as $1.1 billion in Q3 2022 and fell as low as $578.3 million in Q4 2025.
• Historically, Current Assets has averaged $809.0 million across 5 years, with a median of $809.2 million in 2024.
• Across the five-year window, Current Assets soared 70.09% in 2022 and decreased 28.54% in 2025, its largest moves.
• Year by year, Current Assets stood at $1.0 billion in 2022, then retreated by 24.46% to $770.1 million in 2023, then advanced by 5.08% to $809.2 million in 2024, then dropped by 28.54% to $578.3 million in 2025, then advanced by 13.87% to $658.5 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $658.5 million in Q1 2026, $578.3 million in Q4 2025, and $624.0 million in Q3 2025.